CoChat

Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial

Marquis-Gravel, Guillaume, Roe, Matthew T., Robertson, Holly R., Harrington, Robert A., Pencina, Michael J., Berdan, Lisa G., Hammill, Bradley G., Faulkner, Madelaine, Muñoz, Daniel, Fonarow, Gregg C., Nallamothu, Brahmajee K., Fintel, Dan J., Ford, Daniel E., Zhou, Li, Daugherty, Sarah E., Nauman, Elizabeth, Kraschnewski, Jennifer, Ahmad, Faraz S., Benziger, Catherine P., Haynes, Kevin, Merritt, J. Greg, Metkus, Thomas, Kripalani, Sunil, Gupta, Kamal, Shah, Raj C., McClay, James C., Re, Richard N., Geary, Carol, Lampert, Brent C., Bradley, Steven M., Jain, Sandeep K., Seifein, Hani, Whittle, Jeff, Roger, Véronique L., Effron, Mark B., Alvarado, Giselle, Goldberg, Ythan H., VanWormer, Jeffrey L., Girotra, Saket, Farrehi, Peter, McTigue, Kathleen M., Rothman, Russell, Hernandez, Adrian F., Jones, W. Schuyler · 2020 · JAMA Cardiology
Cited by 84

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Importance: Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question. Objective: To report the rationale and design for a randomized clinical trial to determine the optimal dosage of aspirin to be used for secondary prevention of ASCVD, using an innovative research method. Design, Setting, and Participants: This pragmatic, open-label, patient-centered, randomized clinical trial is being conducted in 15 000 patients within the National Patient-Centered Clinical Research Network (PCORnet), a distributed research network of partners including clinical research networks, health plan research networks, and patient-powered research networks across the United States. Patients with established ASCVD treated in routine clinical practice within the network are eligible. Patient recruitment began in April 2016. Enrollment was completed in June 2019. Final follow-up is expected to be completed by June 2020. Interventions: Participants are randomized on a web platform in a 1:1 fashion to either 81 mg or 325 mg of aspirin daily. Main Outcomes and Measures: The primary efficacy end point is the composite of all-cause mortality, hospitalization for nonfatal myocardial infarction, or hospitalization for a nonfatal stroke. The primary safety end point is hospitalization for major bleeding associated with a blood-product transfusion. End points are captured through regular queries of the health systems' common data model within the structure of PCORnet's distributed data environment. Conclusions and Relevance: As a pragmatic study and the first interventional trial conducted within the PCORnet electronic data infrastructure, this trial is testing several unique and innovative operational approaches that have the potential to disrupt and transform the conduct of future patient-centered randomized clinical trials by evaluating treatments integrated in clinical practice while at the same time determining the optimal dosage of aspirin for secondary prevention of ASCVD. Trial Registration: ClinicalTrials.gov Identifier: NCT02697916.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamacardio.2020.0116

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 84

Metadata

Authors
Marquis-Gravel, G., Roe, M. T., Robertson, H. R., Harrington, R. A., Pencina, M. J., Berdan, L. G., Hammill, B. G., Faulkner, M., Muñoz, D., Fonarow, G. C., Nallamothu, B. K., Fintel, D. J., Ford, D. E., Zhou, L., Daugherty, S. E., Nauman, E., Kraschnewski, J., Ahmad, F. S., Benziger, C. P., Haynes, K., Merritt, J. G., Metkus, T., Kripalani, S., Gupta, K., Shah, R. C., McClay, J. C., Re, R. N., Geary, C., Lampert, B. C., Bradley, S. M., Jain, S. K., Seifein, H., Whittle, J., Roger, V. L., Effron, M. B., Alvarado, G., Goldberg, Y. H., VanWormer, J. L., Girotra, S., Farrehi, P., McTigue, K. M., Rothman, R., Hernandez, A. F., & Jones, W. S.
Venue
JAMA Cardiology
Published
2020-05-01
Volume
5
Issue
5
Pages
598
ISSN
2380-6583 (ISSN-L)
OpenAlex
W3011563845
Cited by
84
References
12
FWCI
8.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. https://app.cochat.ai/papers/10.1001/jamacardio.2020.0116
The paper
Marquis-Gravel, G., Roe, M. T., Robertson, H. R., Harrington, R. A., Pencina, M. J., Berdan, L. G., Hammill, B. G., Faulkner, M., Muñoz, D., Fonarow, G. C., Nallamothu, B. K., Fintel, D. J., Ford, D. E., Zhou, L., Daugherty, S. E., Nauman, E., Kraschnewski, J., Ahmad, F. S., Benziger, C. P., . . . Jones, W. S. (2020). Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2020.0116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.